Amyloidosis:The symptoms are related to malfunction or failure of organs or structures infiltrated by amyloid deposits. These symptoms include problems such asheart failure,liverfailure,kidney failure, and blood vessel damage. What Are the First Signs of Multiple Myeloma? Early in the disease, symptom...
Survey of the Italian Registry of Renal Biopsies. Frequency of the renal diseases for 7 consecutive years. The Italian Group of Renal Immunopathology. Renal amyloidosis (39.3%), essential mixed cryoglobulinaemia (30.9%), and multiple myeloma were the most frequent forms in the latter group. In ...
Multiple myeloma and AL (amyloid light chain) amyloidosis refer to plasma cell abnormalities, with multiple organs being affected, most commonly the kidneys and heart. Cardiac involvement can lead to thrombus creation, which is a major cause of embolic ischemic strokes. We report the case of a ...
Echocardiography showed normal atriums, ventricles, valves, and pericardium, with no signs of cardiac amyloidosis. Mammography could not be performed because the patient was unable to stand but breasts were normal on ultrasound. Upper and lower gastrointestinal endoscopies were normal. Pleural aspiration...
Propionic acidaemia is a rare disorder caused by defects in the propionyl-coenzyme A carboxylase α or β (PCCA or PCCB) subunits that leads to an accumulation of toxic metabolites and to recurrent, life-threatening metabolic decompensation events. Here
Sacituzumab govitecan was tested in a basket trial with multiple cohorts, one of which included patients with metastatic triple-negative breast cancer. Early on, the team saw signs of therapeutic efficacy in patients with triple-negative breast cancer, and after discussion with the regulatory author...
Oral administration of histone deacetylase inhibitor MS-275 ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model. J Neuropathol Exp Neurol 72: 178–185. Zheng H, Fridkin M, Youdim M (2014). From single target to multitarget/network therapeutics in Alzheimer...
Though the pioneering developer of RNA interference medicines has already brought five drugs to market, it’s never been profitable. A new approval for one, Onpattro, in a genetic heart condition called transthyretin amyloidosis cardiomyopathy, was expected to finally change that. But the Food and...
Study results are expected in the first half of 2021. CAEL-101 - Caelum Biosciences: Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for light chain (AL) amyloidosis. A pivotal Phase 2/3 program will investigate CAEL-101 as an add-on to current standard-of-care ...
[29]. Further supporting the beneficial role of TREM2-dependent microglial response, systemic administration of TREM2 agonistic antibodies in mouse models of β-amyloidosis has been shown to increase plaque compaction, decrease Aβ burden [30,31], reduce neuritic dystrophy [32], and improve ...